举宫器对IB1至IIA1期宫颈癌的影响:一项回顾性队列研究
该回顾性队列研究分析了2019至2022年间673例接受腹腔镜根治性子宫切除术的FIGO IB1-IIA1期宫颈癌患者,比较使用举宫器组(395例)与未使用组(278例)的生存与手术安全性。结果显示两组3年无病生存率和总生存率均无显著差异,倾向性评分匹配后结果一致。结论认为使用举宫器不影响生存与安全性。
要点
- 举宫器组与未使用组3年无病生存率分别为94.43%和93.88%,无显著差异(P=0.88)。
- 两组3年总生存率分别为98.47%和96.76%,无显著差异(P=0.72)。
- 倾向性评分匹配后3年无病生存率(P=0.53)和总生存率(P=0.94)仍无显著差异。
核心结论
- 在FIGO IB1-IIA1期宫颈癌患者中,腹腔镜根治性子宫切除术中使用举宫器不影响生存和安全性。
研究设计与样本
- 回顾性分析2019至2022年间673例接受腹腔镜根治性子宫切除术的FIGO IB1-IIA1期宫颈癌患者,分为举宫器组(n=395)和无举宫器组(n=278),并进行倾向性评分匹配以尽量减少混杂效应。
主要发现
- 未匹配队列中,举宫器组与无举宫器组3年无病生存率分别为94.43%(95%CI 92.20%-96.72%)和93.88%(95%CI 91.11%-96.74%),P=0.88,无显著差异。
- 未匹配队列中,两组3年总生存率分别为98.47%(95%CI 97.27%-99.69%)和96.76%(95%CI 94.70%-98.86%),P=0.72,无显著差异。
- 倾向性评分匹配后,3年无病生存率(P=0.53)和总生存率(P=0.94)仍无显著差异,5年生存率结果与之一致。
- 匹配后多因素Cox回归分析显示,FIGO分期(2018)IIA1(HR 5.82;95%CI 1.11-30.69;P=0.038)和卵巢侵犯(HR 26.82;95%CI 1.22-589.87;P=0.037)是3年无病生存的独立危险因素。
- 主要术中并发症方面未发现显著差异。
关键数值与推荐
- FIGO分期(2018)IIA1是3年无病生存的独立危险因素(HR 5.82;95%CI 1.11-30.69;P=0.038)。
- 卵巢侵犯是3年无病生存的独立危险因素(HR 26.82;95%CI 1.22-589.87;P=0.037)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the survival and surgical safety of using a uterine manipulator during laparoscopic radical hysterectomy (LRH) for early-stage cervical cancer. METHODS: We retrospectively analyzed 673 patients with FIGO stage IB1 - IIA1 cervical cancer who underwent LRH between 2019 and 2022. Patients were divided into the uterine manipulator group (n = 395) and the uterine manipulator-free group (n = 278). Propensity score matching (PSM) was performed to minimize confounding effects. Statistical analysis was conducted on perioperative characteristics, pathological results, and follow-up data. RESULTS: In the unmatched cohort, no significant differences were observed between the uterine manipulator and uterine manipulator-free groups in 3-year disease-free survival (DFS) rates (94.43 % [95 % CI, 92.20 % - 96.72 %] vs. 93.88 % [95 % CI, 91.11% - 96.74 %]; P = 0.88) or overall survival (OS) rates (98.47 % [95 % CI, 97.27 % - 99.69 %] vs. 96.76 % [95 % CI, 94.70 % - 98.86 %]; P = 0.72). In the PSM-matched cohort, 3-year DFS (P = 0.53) and OS (P = 0.94) also showed no significant difference. Five-year survival rates were consistent with these findings. After PSM, multivariate Cox regression analysis identified FIGO stage (2018) IIA1 (HR, 5.82; 95 % CI, 1.11-30.69; P = 0.038) and ovarian invasion (HR, 26.82; 95 % CI, 1.22-589.87; P = 0.037) as the independent risk factors for 3-year DFS. No significant differences were found in major intraoperative complications. CONCLUSION: In patients with FIGO stage IB1 - IIA1 cervical cancer, uterine manipulator use during laparoscopic radical hysterectomy does not impact survival and safety.
引用
- Bao W, He X, Huang Y, et al. Effect of uterine manipulator on stage IB1 to IIA1 cervical cancer: A retrospective cohort study. Gynecol Oncol. 2025. PMID: 41237597. doi:10.1016/j.ygyno.2025.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。